High Prevalence of Abacavir-associated L74V/I Mutations in Kenyan Children Failing Antiretroviral Therapy

Pediatr Infect Dis J. 2017 Aug;36(8):758-760. doi: 10.1097/INF.0000000000001597.

Abstract

A survey of 461 HIV-infected Kenyan children receiving antiretroviral therapy found 143 (31%) failing virologically. Drug resistance mutations were found in 121; 37 had L74V/I mutations, with 95% receiving abacavir (ABC)-containing regimens. L74V/I was associated with current ABC usage (P = 0.0001). L74V/I may be more prevalent than previously realized in children failing ABC-containing regimens, even when time on treatment has been short. Ongoing rigorous pediatric drug resistance surveillance is needed.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Dideoxynucleosides / pharmacology*
  • Dideoxynucleosides / therapeutic use
  • Drug Resistance, Viral / drug effects*
  • Drug Resistance, Viral / genetics
  • HIV Infections / drug therapy
  • HIV Infections / genetics*
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • Humans
  • Kenya
  • Treatment Failure

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • abacavir